On the Ground at JPM: Key Themes that Could Define Big Pharma Companies in 2024

A quick recap of some of the key themes that may define Big Pharma in 2024, coming out of the annual JP Morgan Healthcare Conference.

Like many of you, I attended the annual JP Morgan Healthcare Conference this year. Braving the rain, hills, naked people yelling in the street (you know you’re in San Francisco when…), and crowded hallways in my uncomfortable dressy shoes, I’ve come back home with a few key themes that could define 2024 in BioPharma. I’ve also likely come back home with some sort of respiratory illness, but so far so good. Hope everyone who attended his staying healthy and upping their vitamin-C.

I’ve always viewed JPM as a tone setter for the rest of the year, especially as it relates to Big Pharma. Some of what Big Pharma says during this meeting is very boilerplate and obvious (“our appetite for M&A remains strong”, “we’re looking for strategic bolt-on acquisitions, but not looking to do a major acquisition at this time”, “we are really impressed by our pipeline progress and think we are going to have a fantastic year’) but this is where we need to read through the lines to really understand what the biggest companies in our sector are prioritizing for the next 12 months. I’ve tried to do my best to summarize this in a clear and concise way below.

By the way, I'm in the process of sourcing sponsors for future posts in 2024. These posts would be 100% accessible to all subscriber levels and get your brand, product, or service in front of my audience of BioPharma Industry decision-makers. If you're interested in becoming a Big Pharma Sharma sponsor, please reach out to me here or on my socials.